Goblet cell density between those with chronic bronchitis and those without chronic bronchitis in the entire cohort (left) and in the COPD subjects alone (right).

<p>Data expressed as goblet cells per millimeter of basement membrane. GC/MM = goblet cells per millimeter basement membrane, CB+ = chronic bronchitis, CB- = no chronic bronchitis, COPD CB+ = COPD subjects with chronic bronchitis, COPD CB- = COPD subjects without chronic bronchitis.</p

Examples of mucosal biopsies from A) a healthy nonsmoker, B) a healthy smoker, C) a COPD subject without chronic bronchitis, and D) a COPD subject with chronic bronchitis, taken at 40x.

<p>Specimens stained with periodic acid Schiff-Alcian Blue, staining goblet cells blue/purple. Basement membrane measured is outlined in red.</p

Baseline Characteristics.

<p>Baseline Characteristics.</p

Goblet cell density in all smokers (smokers without airflow obstruction and COPD subjects that currently smoke) compared with all nonsmokers (healthy nonsmokers and COPD subjects who quit smoking).

<p>A. Data expressed as goblet cells per millimeter of basement membrane. Mucin volume density in all smokers compared with all nonsmokers, B. Data expressed as mean±SE. GC/MM = goblet cells per millimeter basement membrane, MVD = mucin volume density.</p

Characteristics of COPD patients with and without chronic bronchitis.

<p>Characteristics of COPD patients with and without chronic bronchitis.</p

Inclusion and Exclusion Criteria.

<p>Inclusion and Exclusion Criteria.</p

Additional file 3: Table S2. of A randomized trial of the efficacy and safety of quilizumab in adults with inadequately controlled allergic asthma

FEV1 at Week 36 (all patients and biomarker subgroups). (XLSX 48 kb

Additional file 1: of A randomized trial of the efficacy and safety of quilizumab in adults with inadequately controlled allergic asthma

Figure S1. Study design. Figure S2. Pharmacokinetics of quilizumab in asthma patients. Figure S3. Effect of quilizumab on blood eosinophils (A, B) and FeNO (C, D) from baseline to Week 36. (PDF 422 kb